New insulins and other possible therapeutic approaches

Diabetologia

Volumn 40, Issue SUPPL. 3, 1997, Pages

  Johannesen, J ^a   Petersen, K F ^b   Berger, M ^c   Binder, C ^a  

^a STENO DIABETES CENTER   (Denmark)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; C PEPTIDE; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN; PRAMLINTIDE; RECOMBINANT SOMATOMEDIN C;

ABDOMINAL PAIN; ARTHRALGIA; BELL PALSY; BONE PAIN; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; EDEMA; HEADACHE; HUMAN; HYPERPHOSPHATEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; VERTIGO;

AMYLOID; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-LIKE GROWTH FACTOR I;

EID: 0030805365     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051415     Document Type: Conference Paper

References (10)

1. Zinman B, Tildesley H, Chiasson JH, Tsui E, Strack T (1997) Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 46: 440-443
2. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn't. BMJ 312: 71-72
3. Young AA, Wang MW, Gedulin B, Rink TJ, Pittner R, Beaumont K (1995) Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Metabolism 44: 1581-1589
4. Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A (1996) Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC 137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39: 492-499
5. Thompson RG, Pearson L, Gottlieb A, Kolterman OG (1996) Pramlintide, an analog of human amylin, reduced fructosamine in patients with type 1 diabetes. Diabetes 45: [Suppl 2] 222A (Abstract)
6. Wahren J, Johansson B-L, Wallberg-Henriksson H, Linde B, Fernqvist-Forbes E, Zierath J R (1996) C-peptide revisited - new physiological effects and therapeutic implications. J Int Med 240: 115-124
7. Zenobi PD, Glatz Y, Keller A et al. (1994) Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin resistant diabetes type A. Eur J Endocrinol 131: 251-257
8. Dunger DB, Cheetham TD, Crowne EC (1995) Insulin growth factors (IGFs) and IGFI treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism 44: 119-123
9. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR (1996) Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycaemic control in type II diabetes. Diabetes 45: 91-100
10. Mitragotri S, Blankschtein D, Langer R (1995) Ultrasound-mediated transdermal protein delivery. Science 269: 850-853